In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings together the seven most interesting cancer companies in the Nordic region for a discussion about the major changes in progress and how the companies position themselves in this fast growing theraputic area worth over $ 100 billion a year.
Isofol is presented at 09.40 and will present its clinical activities and the cancer drug candidate, Arfolitixorin, which is primarily intended for the treatment of advanced colorectal cancer. Isofol will also talk about the expected highlights of ASCO. Futher the program offers two panel discussions on themes Why is ASCO important to attend and Trends in the cancer area.
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB (publ)
Phone: +46 (0)707 646 500
Arfolitixorin is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. The active ingredient in arfolitixorin, [6R]-5,10-methylenetetrahydrofolate, is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin is suitable for all patients irrespective of their capacity to activate folates since it does not require metabolic activation to exert its effect.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a drug development company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.